Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Taladegib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101
    Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101

    06 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230906375636/en

    BUSINESSWIRE
    06 Sep 2023
    Share Share
    Endeavor Doses First Patient in Phase 2 Oncology Study of ENV-101 (Taladegib)
    Endeavor Doses First Patient in Phase 2 Oncology Study of ENV-101 (Taladegib)

    25 May 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220525005283/en

    BUSINESSWIRE
    25 May 2022
    Share Share
    Endeavor Bio Closes $101M Series B Financing for Precision Medicine Pipeline
    Endeavor Bio Closes $101M Series B Financing for Precision Medicine Pipeline

    07 Feb 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220207005151/en

    BUSINESSWIRE
    07 Feb 2022
    Share Share
    Endeavor BioMedicines Doses First Patient in Phase 2 of Taladegib for IPF
    Endeavor BioMedicines Doses First Patient in Phase 2 of Taladegib for IPF

    22 Sep 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210922005035/en

    BUSINESSWIRE
    22 Sep 2021
    Share Share